Introduction

This report highlights how drug repositioning can provide a low-risk approach to drug development. The success of the approach is illustrated by a number of case histories, mostly arising from serendipitous observations. The report illustrates systematic approaches to identify suitable opportunities that should lead to better success including those being pursued by specialist companies.

Features and benefits

* Analyze and understand the strategies employed in the most successful examples of drug repositioning. * Discover the key technologies required to establish potential repositioning opportunities. * Identify the specialist service providers with expertise in the key technologies required to systematically identify repositioning candidates. * Discover how through repositioning a company can protect its intellectual property. * Analyze the potential impact that drug repositioning can have on both large pharma companies and small specialist companies.

Highlights

The pharma industrys revenue growth is low and it is failing to introduce sufficient new drugs to offset the impact of patent expirations despite record R&D costs. Repurposing of drugs offers a lower risk, lower cost, approach to new product development. Repurposing of development failures can recover what would otherwise be lost R&D expenditure. The potential commercial benefits from successful repositioning of a drug are likely to be greater than those offered by simple reformulation, and offers opportunities for extended periods of market exclusivity via the granting of additional patents. Major companies are well positioned to benefit from the successful repurposing of drugs, especially when they utilize both internal resources and external resources. The effective application of repurposing technologies should enable major companies to significantly enhance their development pipelines.

Your key questions answered

* What are the current advantages of repositioning over other lower risk approaches to drug development? * What are the key technologies being used to identify new targets for molecules in companies databases? * How does drug repositioning improve the intellectual property position of companies that employ this strategy? * What skills and platforms do specialist companies engaged in drug repositioning possess? * How have molecules such as sildenafil and thalidomide been repositioned successfully?

"
Executive Summary
Chapter 1 Introduction
Chapter 2 Lower Risk Strategies
Chapter 3 What is Repositioning?
Chapter 4 Strategic Approaches to Repositioning
Chapter 5 Successful case studies
Chapter 6 Current Efforts
Chapter 7 Specialist Companies
Chapter 8 Outlook
About the author
Disclaimer
Introduction
Summary
Introduction
The decline in approvals of novel chemical entities
The costs, and risks, of drug development
Lower Risk Strategies
Summary
Introduction
Enantiomeric switches
Active metabolites
Reformulation
Repositioning
What is Repositioning?
Summary
Overview
Commercial implications
Intellectual property issues
Design or serendipity?
Strategic Approaches to Repositioning
Summary
Introduction
Chemical space
New indications
Phenotypic approaches
Informatics-based approaches
Reformulation
Exploiting intellectual property
Increased licensing opportunities
Succesful case studies
Summary
Introduction
Bupropion
Minoxidil
Thalidomide
Bosentan
sildenafil (Viagra and Revatio)
Current Efforts
Summary
Introduction
Major opportunities
Rare diseases
Drugs in advanced development
Inhaled formulations
Biological products
Modified formulations
Repurposing by combination
Other approaches
Specialist Companies
Summary
Introduction
Almac Group
Ampio Pharmaceuticals
Anaxomics Biotech
APT Pharmaceuticals
Aureus Sciences
Biovista
Celentyx
Cypress Bioscience
Essentialis
Horizon Discovery
Jenken Biosciences
Melior Discovery
NeuroHealing Pharmaceuticals
Numedicus
OphSmart
Optimata
Ore Pharmaceutical Holdings
Radical Therapeutix
SOM Biotech
Somaxon Pharmaceuticals
Sosei Group
SWITCH Biotech
Tangent Reprofiling
Zalicus
Outlook
Summary
Introduction
Impact on major companies
Impact for specialist companies
Overall perspective
Appendix
Glossary/Abbreviations
Bibliography/References
"